Urinary bladder cancer (UBC) is among the well-known forms of malignant urinary tract tumors. Among malignant neoplasms, this disease is the eights most widespread in women and fourth - in men. 80% of UBC cases occur in men.
Upon manifestation, the new tumors are diagnosed as muscle-invasive carcinomas (stages Т2-T4aN0M0) in 30% of cases. The choice of a specialized therapy for patients with UBC is based on the results of histological verification, depth of invasion, degree of advancement and state of differentiation of the tumor. The use of the possibilities of intra-arterial infuse of chemotherapeutic agents remains relevant in treating patients with on-courological diseases for many years.
The application of regional polychemotherapy for treating patients with UBC (stages T3a-T4nN0-1M0G2-3) is more effective in 61% of cases. This approach is justified if a patient has contraindications for radical surgical treatment or if he refuses to undergo surgery or in case of the possibility to conduct interventional procedures in expert-level outpatient clinics. Minimization of side effects during regional polychemotherapy is possible in case of selective intra-arterial delivery of the drug to the tumor, which should be combined with the reduction of the dose of the main active substance (Cis-platin). The life expectancy has exceeded 10 years in 25% of patients after regional polychemotherapy, which clearly indicates the necessity of further research in this field.
Authors declare lack of the possible conflicts of interests.